Cencora (COR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
14 Jun, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of eleven directors at the 2025 Annual Meeting scheduled for March 6, 2025.
An advisory vote will be held to approve the fiscal 2024 compensation of named executive officers.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal 2025 is on the agenda.
Proxy holders may vote on other business that may properly come before the meeting.
Board of directors and corporate governance
Eleven nominees are presented for election to the board, including individuals with diverse backgrounds and expertise.
Executive compensation and say-on-pay
Shareholders are asked to provide an advisory vote on the compensation of named executive officers for fiscal 2024.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cencora
- Adjusted EPS and revenue climbed double digits, with 2025 growth and RCA deal ahead.COR
Q4 20249 Jul 2026 - Raised guidance and specialty investments drive strong growth and long-term confidence.COR
Barclays 28th Annual Global Healthcare Conference9 Jul 2026 - Specialty growth, biosimilars, and disciplined capital deployment drive strong performance.COR
43rd Annual J.P. Morgan Healthcare Conference8 Jul 2026 - Guidance reaffirmed, growth to accelerate, $1B buybacks planned, and AI-driven efficiencies prioritized.COR
Bank of America Global Healthcare Conference 202613 May 2026 - Q2 FY2026 delivered 3.8% revenue growth, higher EPS, and a $1.1B OneOncology gain.COR
Q2 20266 May 2026 - Q1 FY2026 revenue up 5.5% to $85.9B; adjusted EPS rose 9.4% to $4.08.COR
Q1 202613 Apr 2026 - Expanded MSO ownership and robust specialty growth drive higher guidance and strategic focus.COR
Leerink Global Healthcare Conference 202610 Mar 2026 - All proposals passed, with strong financial growth and major strategic investments announced.COR
AGM 20269 Mar 2026 - Q3 revenue up 10.9% to $74.2B; adjusted EPS up 14.4%; FY2024 guidance raised.COR
Q3 20242 Feb 2026